Please assess the completion status of the following clinical trial:

Trial Title: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed PTCL NOS, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma nasal type, enteropathy- type T-cell lymphoma, hepatosplenic T-cell lymphoma, ALCL (ALK-1 negative), or patients with ALK 1 expressing ALCL (ALK-1 positive) who have relapsed disease after ASCT~* Age ≥21 years~* Written informed consent~* Progressive disease following at least one systemic therapy or refractory to at least one prior systemic therapy~* Measurable disease according to the IWC criteria and/or measurable bone marrow disease by flow cytometry or morphology~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Absolute neutrophil count of ≥1000 × 10(9)cells/L~* Serum potassium ≥3.8 mmol/L and magnesium ≥0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria)~* Negative urine or serum pregnancy test on females of childbearing potential~* All females of childbearing potential and males must use an effective barrier method of contraception during the treatment period and for at least 1 month thereafter.~Exclusion Criteria:~* Chemotherapy or immunotherapy within 3 weeks of study entry~* Concomitant use of any other anti-cancer therapy~* Concomitant use of any other investigational agent~* Any known cardiac abnormalities such as:~  * Congenital long QT syndrome;~ * QTcF interval \>480 milliseconds (msec);~ * A myocardial infarction within 12 months of study entry;~ * Other significant ECG abnormalities including 2nd atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate \< 50 beats/ min).~ * An ECG recorded at screening showing significant ST depression (ST depression of ≥2 mm, measured from isoelectric line to the ST segment at a point 60 msec at the end of the QRS complex). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;~ * Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction \<40% by MUGA scan or \<50% by echocardiogram and/or MRI;~ * A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);~ * Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above);~ * Any cardiac arrhythmia requiring anti-arrhythmic medication;~* Serum potassium \<3.8 mmol/L or serum magnesium \<0.85 mmol/L (electrolyte abnormalities can be corrected with supplementation to meet inclusion criteria)~* Concomitant use of drugs that may cause a prolongation of the QTcF~* Concomitant use of CYP3A4 inhibitors~* Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule~* Concomitant use of warfarin due to a potential drug interaction~* Clinically significant active infection~* Known infection with human immunodeficiency virus (HIV)~* Patient has known clinically active hepatitis B or C~* Previous extensive radiotherapy involving ≥30% of bone marrow (e.g., whole pelvis, half spine), excluding patients who have had total body irradiation as part of a conditioning regimen for stem cell transplant~* Major surgery within 2 weeks of study entry~* Peripheral neuropathy or neuropathic pain of Grade 2 or worse~* Platelet count \<50 × 109 cells/L or platelet count \<30 × 109 cells/L if bone marrow disease involvement is documented~* Serum creatinine \>2.0 × ULN~* Patients who are pregnant or breast-feeding~* Patient has known hypersensitivity to any components of bortezomib (such as boron, mannitol), or panobinostat

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- panobinostat and bortezomib (Type: EXPERIMENTAL): Oral Panobinostat and intravenous bortezomib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete